Latest Conference Articles

October 4th 2012, 7:25am

ESMO Congress: Head and Neck Cancer

Ezra Cohen, MD, from the University of Chicago Medical Center, discusses the impact of cabozantinib's dose size on tolerability.

October 3rd 2012, 1:18pm

ESMO Congress

Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.

October 3rd 2012, 10:14am

ESMO Congress: GI Cancers

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

October 3rd 2012, 8:50am

ESMO Congress

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

October 3rd 2012, 6:33am

ESMO Congress: Breast Cancer

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

October 2nd 2012, 11:48am

ESMO Congress: Gynecologic Cancers

An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.

October 2nd 2012, 9:53am

ESMO Congress

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

October 2nd 2012, 9:10am

ESMO Congress: GU Cancers

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

October 1st 2012, 11:35am

ESMO Congress: Breast Cancer

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

October 1st 2012, 8:38am

ESMO Congress: Lung Cancer

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

October 1st 2012, 7:48am

ESMO Congress: GI Cancers

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

September 30th 2012, 1:55pm

ESMO Congress: Head and Neck Cancer

Ezra E.W. Cohen, MD, from the University of Chicago Medical Center, on the pharmacokinetics and efficacy of cabozantinib for medullary thyroid cancer.

September 30th 2012, 5:10am

ESMO Congress: GI Cancers

Two analyses, two different conclusions in Asian START trial when docetaxel was added to S-1 for patients with previously untreated advanced or recurrent gastric cancer.

September 29th 2012, 3:42pm

ESMO Congress

Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.

September 29th 2012, 3:27pm

ESMO Congress: GI Cancers

Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

September 25th 2012, 12:25pm

Annual Meeting of the American Thyroid Association

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

September 25th 2012, 11:36am

Annual Meeting of the American Thyroid Association

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

September 25th 2012, 9:05am

Annual Meeting of the American Thyroid Association

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

September 24th 2012, 2:15pm

Annual Meeting of the American Thyroid Association

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

September 24th 2012, 12:13pm

Annual Meeting of the American Thyroid Association

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.